Affordable Access

deepdyve-link
Publisher Website

Smac Mimetics to Therapeutically Target IAP Proteins in Cancer.

Authors
  • Fulda, S1
  • 1 Institute for Experimental Cancer Research in Pediatrics, Goethe-University, Frankfurt, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address: [email protected]
Type
Published Article
Journal
International review of cell and molecular biology
Publication Date
2017
Volume
330
Pages
157–169
Identifiers
DOI: 10.1016/bs.ircmb.2016.09.004
PMID: 28215531
Source
Medline
Keywords
License
Unknown

Abstract

Inhibitor of Apoptosis (IAP) proteins are overexpressed in a variety of human cancers. Therefore, they are considered as promising targets for the design of therapeutic strategies. Smac mimetics mimic the endogenous mitochondrial protein Smac that antagonizes IAP proteins upon its release into the cytosol. Multiple preclinical studies have documented the ability of Smac mimetics to either directly induce cell death of cancer cells or to prime them to agents that trigger cell death. At present, several Smac mimetics are being evaluated in early clinical trials. The current review provides an overview on the potential of Smac mimetics as cancer therapeutics to target IAP proteins for cancer therapy.

Report this publication

Statistics

Seen <100 times